Global Hydrogel for Drug Delivery Market Size, Share, Growth, Industry Analysis By Polymer Origin (Natural, Synthetic, Hybrid), By Delivery Route (Injectable, Oral, Topical & Transdermal, Ocular), By Application (Cancer Therapy, Wound Healing, Tissue Engineering & Regenerative Medicine), By End User (Hospitals & Clinics, Pharma & Biotech Companies, Research Institutes), Regional Analysis & Key Players - Market Dynamics, Competitive Strategies & Forecast 2026-2034

Name: Global Hydrogel for Drug Delivery Market Size, Share, Growth, Industry Analysis By Polymer Origin (Natural, Synthetic, Hybrid), By Delivery Route (Injectable, Oral, Topical & Transdermal, Ocular), By Application (Cancer Therapy, Wound Healing, Tissue Engineering & Regenerative Medicine), By End User (Hospitals & Clinics, Pharma & Biotech Companies, Research Institutes), Regional Analysis & Key Players - Market Dynamics, Competitive Strategies & Forecast 2026-2034
Brand: IntelEvoResearch
SKU: IR-1597
Rating: 5 (1 reviews)

Published : 21 Jul 2026

Report ID: IR1597

Pages : 241

Format :

Summary Table of Content Major Market Players DROT Recent Development Inquiry Before Buying

Report Overview

Market Size (2025)	Forecast Value (2034)	CAGR (2026-2034)	Largest Region (2025)
USD 8.85 Billion	USD 18.40 Billion	8.5%	North America, 43.0%

The Hydrogel for Drug Delivery Market was valued at USD 8.24 Billion in 2024 and reached USD 8.85 Billion in 2025. The market is projected to reach USD 18.40 Billion by 2034, expanding at a CAGR of 8.5% during the forecast period from 2026 to 2034. This represents an absolute dollar opportunity of USD 9.55 Billion over the analysis period.

Hydrogel for Drug Delivery Market Size

Get More Information about this report -

Request Free Sample Report

Demand for the hydrogel for drug delivery market is anchored by ophthalmology, oncology, wound care, and pain management applications where controlled release kinetics, site-specific targeting, and biocompatibility outperform conventional formulation technologies. Three FDA approvals reshaped the commercial landscape across 2025. On February 4, 2025, the FDA approved Genentech's Susvimo (ranibizumab injection) for diabetic macular edema, marking the second indication for the Port Delivery Platform after wet AMD. On May 22, 2025, the FDA cleared Susvimo for diabetic retinopathy, with refills required only every nine months in the Pavilion Phase 3 protocol. On June 12, 2025, UroGen Pharma secured FDA approval for ZUSDURI (UGN-102), an intravesical mitomycin formulation built on the proprietary RTGel reverse-thermal hydrogel platform, for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The Phase 3 ENVISION trial reported a 79.6% complete response rate at three months, with 79% of responders remaining event-free at one year.

Regulatory and reimbursement frameworks shape commercial adoption across the hydrogel for drug delivery market. The U.S. Food and Drug Administration regulates hydrogel-based drug delivery products through the Center for Drug Evaluation and Research for drug-device combination products, while the European Medicines Agency operates the centralized procedure for parallel review. Medicare reimbursement under HCPCS Level II J-codes covers approved ophthalmic implants such as Susvimo, while UroGen secured permanent J-code J9281 for Jelmyto and provisional pricing for ZUSDURI. The Centers for Medicare & Medicaid Services issued a National Coverage Determination supporting payer adoption of sustained-release ocular implants, while reimbursement under MS-DRGs in inpatient settings supports oncology hydrogel deployment. Per WHO data cited in industry analyses, the global burden of chronic disease is forecast to expand 57% by 2030, expanding the addressable population for hydrogel sustained-release platforms in oncology, ophthalmology, and pain management.

Innovation across the hydrogel for drug delivery market follows three vectors. First, stimuli-responsive smart hydrogels that respond to pH, temperature, enzymatic activity, redox potential, and light enable on-demand release profiles tailored to disease microenvironments. Second, theranostic platforms integrate hydrogel scaffolds with imaging agents such as magnetic nanoparticles, fluorescent dyes, and radiolabeled isotopes for real-time therapeutic monitoring during cancer treatment. Third, particulate hydrogel formats such as microgels and nanogels address syringeability constraints for posterior eye, intra-articular, and tumor margin applications. North America captured 43.0% of 2025 revenue, while Asia Pacific is forecast to register the fastest 10.2% CAGR through 2034, supported by aging demographics, expanded healthcare infrastructure, and rising chronic disease prevalence in China, Japan, and South Korea.

Market Definition and Scope

The hydrogel for drug delivery market is defined as the global commercial supply of three-dimensional, cross-linked, hydrophilic polymer networks formulated with active pharmaceutical ingredients (APIs) for sustained, controlled, targeted, or stimuli-responsive therapeutic release across pharmaceutical and combination drug-device products. The market includes natural-polymer hydrogels (collagen, gelatin, alginate, chitosan, hyaluronic acid, dextran, pectin, xanthan gum), synthetic-polymer hydrogels (polyethylene glycol, polyvinyl alcohol, polyacrylic acid, poly(2-hydroxyethyl methacrylate), polylactic-co-glycolic acid), hybrid hydrogels combining natural and synthetic polymers, and stimuli-responsive (smart) hydrogels engineered to respond to pH, temperature, enzymatic activity, redox potential, or light triggers.

Included in this analysis are injectable hydrogels, in-situ-forming hydrogels, intravesical hydrogels, intravitreal hydrogels, ocular implants, transdermal hydrogel patches, oral hydrogels, buccal and vaginal hydrogels, hydrogel-coated medical devices for drug elution, and hydrogel-based microneedle patches. Excluded from scope are wound-care hydrogels intended primarily for moisture donation rather than API delivery, hydrogel scaffolds for tissue engineering without therapeutic payload, contact lenses, hygiene products incorporating superabsorbent polymers, agricultural hydrogels, and hydrogel-based medical adhesives without active drug release. The hydrogel for drug delivery market sits inside the broader pharmaceutical drug delivery technology market and accounts for approximately 4.7% of total global drug delivery revenue in 2025.

Key Takeaways

Market Growth: The hydrogel for drug delivery market reached USD 8.85 Billion in 2025 and is projected to reach USD 18.40 Billion by 2034 at an 8.5% CAGR.
Segment Dominance: By polymer origin, synthetic-polymer hydrogels captured 48.6% of 2025 revenue equivalent to USD 4.30 Billion, anchored by FDA-approved Susvimo, ZUSDURI, and Zilretta formulations.
Segment Dominance: By delivery route, ophthalmic hydrogels accounted for 27.4% of 2025 revenue, while topical hydrogels are forecast to register the fastest 10.0% CAGR through 2034.
Driver: Three FDA approvals in 2025, including Susvimo for diabetic macular edema (February 4), Susvimo for diabetic retinopathy (May 22), and ZUSDURI for low-grade intermediate-risk NMIBC (June 12), validated commercial scale-up of sustained-release hydrogel platforms.
Restraint: Manufacturing scale-up costs for medical-grade hydrogel APIs run 6 to 10 times conventional formulations, with sterility validation, biocompatibility testing, and multi-phase clinical trials extending commercialization timelines beyond eight years for novel hydrogel chemistries.
Opportunity: Injectable oncology hydrogels are forecast to expand at an 11.2% CAGR through 2034, with chemo-immunotherapy combination depots and stimuli-responsive tumor-microenvironment platforms anchoring the pipeline.
Trend: Theranostic hydrogel platforms integrating MRI contrast agents, fluorescent probes, and radiolabeled tracers are advancing through preclinical and Phase 1 studies for real-time therapeutic monitoring in oncology and ophthalmology.
Regional: North America held the leading regional position at 43.0% revenue share equivalent to USD 3.81 Billion in 2025, anchored by Genentech, UroGen Pharma, Pacira BioSciences, and Ocular Therapeutix commercial product lines.

Key Insights Summary

On June 12, 2025, the FDA approved UroGen Pharma's ZUSDURI (UGN-102) for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, with the Phase 3 ENVISION trial reporting a 79.6% complete response rate at three months and 79% durability at one year using the proprietary RTGel reverse-thermal hydrogel.
On February 4, 2025, Genentech secured FDA approval for Susvimo (ranibizumab injection) for diabetic macular edema based on the Pagoda Phase 3 study, where 6-month refills delivered non-inferior visual acuity gains of 9.6 ETDRS letters versus 9.4 letters for monthly intravitreal injections in 634 randomized patients.
On May 22, 2025, the FDA expanded Susvimo's label to include diabetic retinopathy, the first continuous delivery treatment for the condition, with the Pavilion Phase 3 study demonstrating diabetic retinopathy severity scale improvements of two or more steps at 52 weeks with refill intervals of nine months.
On December 11, 2025, NEXGEL Inc. spun off its prescription drug delivery program into NexGelRx with initial outside investor funding, retaining a 19.99% non-dilutive equity stake and a 5% perpetuity royalty on global Rx applications of NEXGEL's electron-beam-cross-linked hydrogel platform.
An October 2025 MDPI peer-reviewed analysis sized injectable hydrogel applications across ocular, intra-articular, subcutaneous, intramuscular, tumoral, central nervous system, and mucosal delivery, with stimuli-responsive variants including thermosensitive, enzyme-cleavable, and pH-sensitive moieties matching pathological features such as inflammation and acidic tumor microenvironments.
Pacira BioSciences' Zilretta (triamcinolone acetonide), an FDA-approved intra-articular injectable formulation comprising approximately 50-micron PLGA microspheres with sustained release over several weeks, anchors the commercial intra-articular sub-segment for osteoarthritis pain management.

Competitive Landscape Overview

The hydrogel for drug delivery market is moderately fragmented. Specialty pharmaceutical companies including Genentech (Roche), UroGen Pharma, Pacira BioSciences, and Ocular Therapeutix anchor the commercial drug-product segment with FDA-approved hydrogel formulations across ophthalmology, oncology, and pain management. Polymer and excipient suppliers including Ashland Global Holdings, Lubrizol Life Sciences, BASF, and Royal DSM serve formulation R&D programs across pharma and medtech accounts. Wound care and medical device firms including Cardinal Health, Johnson & Johnson, Smith & Nephew, ConvaTec, Coloplast, B. Braun Melsungen, and Paul Hartmann support hydrogel platforms across hospital and clinic settings. Strategic levers run along three lines: FDA approval velocity for new hydrogel-API combinations, polymer formulation IP including stimuli-responsive chemistries, and commercial reimbursement coverage including J-code assignments. Strategic activity over the trailing 12 months centered on FDA approvals, label expansions, corporate spin-offs, and bolt-on acquisitions of polymer suppliers rather than mega-deals.

Competitive Landscape Matrix

Company	Headquarters	Market Position	Key Product	Geographic Strength	Recent Strategic Move
Genentech (Roche)	South San Francisco, CA, USA	Leader	Susvimo (ranibizumab) Port Delivery Platform	Global	Earned FDA approval for Susvimo for diabetic retinopathy on May 22, 2025
UroGen Pharma Ltd.	Princeton, NJ, USA / Israel	Leader	ZUSDURI (UGN-102), Jelmyto, RTGel platform	North America	Secured FDA approval for ZUSDURI for LG-IR-NMIBC on June 12, 2025
Pacira BioSciences	Tampa, FL, USA	Challenger	Zilretta (triamcinolone acetonide) PLGA microspheres	North America, Europe	Continued commercial scale-up of Zilretta for intra-articular osteoarthritis pain
Ocular Therapeutix	Bedford, MA, USA	Challenger	OTX-TIC, OTX-IVT bioresorbable hydrogel implants	North America	Advanced OTX-TIC bioresorbable intracameral travoprost implant in Phase 1/2 glaucoma trials
Cardinal Health Inc.	Dublin, OH, USA	Leader	Hydrogel-based drug delivery and wound care products	Global	Maintained leading position in hospital and clinic distribution channels
Johnson & Johnson	New Brunswick, NJ, USA	Leader	Hydrogel-based drug delivery formulations	Global	Continued portfolio expansion across ophthalmic and surgical hydrogel applications
Merck KGaA	Darmstadt, Germany	Leader	Hydrogel-based drug delivery and biopharma supply	Global	Closed USD 3.4 Billion acquisition of SpringWorks Therapeutics in 2025
Ashland Global Holdings	Wilmington, DE, USA	Challenger	Pharmaceutical hydrogel polymers and excipients	Global	Continued expansion of Klucel and Aquasolve hydrogel polymer lines
Lubrizol Life Science	Wickliffe, OH, USA	Challenger	Carbopol hydrogel polymers, formulation services	Global	Maintained drug delivery polymer leadership across topical and ophthalmic categories
ConvaTec Group PLC	Reading, UK	Niche Player	Hydrogel-based wound care and ostomy products	Europe, North America	Continued geographic expansion across emerging markets in 2025
NEXGEL Inc.	Langhorne, PA, USA	Niche Player	Electron-beam cross-linked hydrogel platform	North America	Spun off Rx drug delivery program into NexGelRx on December 11, 2025
Smith & Nephew plc	London, UK	Challenger	Hydrogel wound care and surgical drug delivery	Global	Continued commercial expansion across advanced wound care portfolio

By Polymer Origin

Synthetic-polymer hydrogels dominated the hydrogel for drug delivery market with 48.6% of 2025 revenue equivalent to USD 4.30 Billion. Polyethylene glycol, polyvinyl alcohol, polyacrylic acid, poly(2-hydroxyethyl methacrylate), and PLGA chemistries anchor commercial product lines including Genentech's Susvimo Port Delivery Platform, UroGen's RTGel reverse-thermal platform underpinning Jelmyto and ZUSDURI, and Pacira BioSciences' Zilretta PLGA microsphere formulation. Synthetic chemistries deliver tunable mechanical strength, controlled degradation rates, and reproducible manufacturing scale-up advantages that natural polymers cannot match, supporting their continued lead.

Natural-polymer hydrogels captured 36.7% of 2025 revenue and are forecast to grow at a 9.4% CAGR through 2034, the fastest among polymer-origin classes. Collagen, gelatin, alginate, chitosan, hyaluronic acid, dextran, pectin, xanthan gum, and fibrin anchor the natural sub-segment, with biocompatibility, biodegradability, and extracellular matrix mimicry driving demand across oncology depot, wound healing, and tissue-engineering-adjacent applications. Hybrid hydrogels combining natural and synthetic polymers held the remaining 14.7% of revenue, with crosslinker chemistries including dibenzocyclooctyne-functionalized poly(L-glutamic acid) and copper-free strain-promoted azide-alkyne cycloaddition supporting in-situ-forming depot platforms in oncology trials.

By Delivery Route

Ophthalmic hydrogels captured 27.4% of the hydrogel for drug delivery market in 2025, equivalent to USD 2.42 Billion. Genentech's Susvimo Port Delivery Platform, FDA-approved across wet AMD, diabetic macular edema, and diabetic retinopathy, anchors the commercial ophthalmic segment alongside Ocular Therapeutix's OTX-TIC bioresorbable intracameral travoprost implant. Sustained intraocular release of anti-VEGF therapeutics (ranibizumab, aflibercept) addresses patient adherence challenges and reduces injection frequency from monthly to every six or nine months, supporting the segment's commercial leadership.

Injectable hydrogels accounted for 24.6% of 2025 revenue and are forecast to grow at an 11.0% CAGR through 2034, the fastest among delivery routes, supported by oncology depot platforms and intra-articular pain management applications. Pacira BioSciences' Zilretta and emerging chemo-immunotherapy hydrogel depots based on matrix metalloproteinase-responsive polypeptide chemistries anchor the injectable segment. Topical hydrogels captured 19.8% of revenue, with the segment expected to grow at 10.0% CAGR through 2034 supported by Beiersdorf's January 2025 Hansaplast hydrogel format launches and Biomiq's PureGel nanotechnology-based wound care launch in February 2025. Intravesical hydrogels held 11.6% of revenue, anchored by UroGen's Jelmyto and ZUSDURI commercial portfolio. Other delivery routes including transdermal patches, oral, buccal, and vaginal hydrogels collectively accounted for 16.6% of 2025 revenue.

By Application

Oncology applications captured 28.3% of the hydrogel for drug delivery market in 2025, equivalent to USD 2.50 Billion. Bladder cancer led oncology revenue through UroGen's Jelmyto and June 12, 2025-approved ZUSDURI commercial product lines. Solid-tumor injectable hydrogel depots including OncoGel (paclitaxel) and chemo-immunotherapy combination platforms based on dibenzocyclooctyne-functionalized polypeptide chemistries advanced through Phase 1 and Phase 2 trials. The application is forecast to grow at a 10.4% CAGR through 2034, supported by tumor-microenvironment-responsive smart hydrogel pipelines.

Ophthalmology accounted for 26.7% of 2025 revenue, anchored by wet AMD, diabetic macular edema, and diabetic retinopathy applications across Susvimo, Ozurdex, Iluvien, Yutiq, and Retisert FDA-approved sustained-release platforms. Pain management captured 17.4% of revenue, anchored by intra-articular triamcinolone acetonide formulations such as Pacira BioSciences' Zilretta and emerging hyaluronic-acid-based osteoarthritis depots. Wound care held 14.5% of revenue, while cardiovascular, immunology, dermatology, and other applications collectively accounted for 13.1% of 2025 revenue.

By End User

Hospitals captured 47.8% of 2025 hydrogel for drug delivery market revenue, anchored by inpatient ophthalmic surgery, oncology infusion, and pain management procedure volumes. Specialty clinics including ophthalmology centers, urology clinics, and oncology infusion centers represented 28.2% of revenue, with retina specialist offices and academic medical centers anchoring outpatient Susvimo refill procedures and ZUSDURI intravesical instillations. Ambulatory surgery centers held 13.6% of revenue, while research institutes, contract research organizations, and pharma/biotech R&D end users collectively accounted for 10.4% of 2025 revenue.

Regional Analysis

North America generated USD 3.81 Billion in hydrogel for drug delivery market revenue in 2025, equivalent to 43.0% of global share. The United States anchors regional demand through Genentech's Susvimo commercial deployment across wet AMD, diabetic macular edema, and diabetic retinopathy indications, UroGen Pharma's Jelmyto and ZUSDURI bladder cancer products, Pacira BioSciences' Zilretta intra-articular product line, and Ocular Therapeutix's OTX-TIC pipeline. The Centers for Medicare & Medicaid Services issued National Coverage Determinations supporting payer adoption of sustained-release ocular implants, while UroGen secured permanent J-code J9281 for Jelmyto and provisional pricing for ZUSDURI. Canadian Health Canada approvals lag U.S. FDA approvals by 6 to 18 months, with Biomiq's PureGel nanotechnology-based hydrogel licensed as a Class II medical device in Canada in February 2025.

Europe contributed USD 2.12 Billion or 24.0% of 2025 revenue. The European Medicines Agency's centralized procedure governs hydrogel-based drug-device combination product approvals, with Germany, the United Kingdom, France, Italy, and Spain anchoring regional demand. Merck KGaA's USD 3.4 Billion acquisition of SpringWorks Therapeutics in 2025 broadened the German pharma group's rare disease and oncology footprint, supporting hydrogel formulation R&D. Beiersdorf's January 2025 Hansaplast/Second Skin wound care portfolio expansion with hydrogel-based invisible spray and liquid formats anchored consumer hydrogel format innovation across European retail channels.

Asia Pacific produced USD 1.95 Billion in 2025, holding 22.0% of revenue, and is forecast to register the fastest 10.2% CAGR through 2034. China leads regional growth on the back of expanded healthcare infrastructure, rising chronic disease prevalence, and academic R&D programs at Chinese Academy of Sciences (Changchun Institute of Applied Chemistry), University of Science and Technology of China, and Tsinghua. Japan's hydrogel R&D base anchored by Tokyo University, Kyoto University, and Sanyo Chemical supports premium ophthalmic and dermatological applications. South Korea's LG Chem and Sumitomo Seika provide regional polymer supply, while India's expanded pharmaceutical manufacturing footprint supports regional contract development and manufacturing organization (CDMO) capacity. The senior population growth across the Asia-Pacific region anchors regional demand expansion through 2034.

Latin America accounted for USD 575 Million or 6.5% of 2025 revenue. Brazil leads regional demand through ANVISA-regulated pharmaceutical commercialization and the public Sistema Único de Saúde reimbursement framework. Mexico, Argentina, Colombia, and Chile support secondary regional activity. The Middle East and Africa region contributed USD 398 Million or 4.5% of 2025 revenue, anchored by GCC pharmaceutical procurement programs in Saudi Arabia, the UAE, and Qatar, with South Africa supporting Sub-Saharan demand.

Country Analysis

The United States hydrogel for drug delivery market reached USD 3.45 Billion in 2025 and is projected to expand at an 8.0% CAGR through 2034. Manufacturing concentration in South San Francisco, California (Genentech), Princeton, New Jersey (UroGen Pharma), Tampa, Florida (Pacira BioSciences), Bedford, Massachusetts (Ocular Therapeutix), and Wilmington, Delaware (Ashland Global Holdings) anchors domestic supply. FDA approval velocity accelerated across 2025 with three high-impact clearances including Susvimo for diabetic macular edema (February 4), Susvimo for diabetic retinopathy (May 22), and ZUSDURI for LG-IR-NMIBC (June 12). The Centers for Medicare & Medicaid Services Medicare Physician Fee Schedule and Outpatient Prospective Payment System support sustained reimbursement for approved hydrogel products.

Germany generated USD 532 Million in 2025 with a country CAGR of 7.8% projected through 2034. Merck KGaA's pharmaceutical headquarters in Darmstadt, Paul Hartmann's Heidenheim wound care operations, and academic R&D at the Max Planck Institutes anchor domestic supply. Statutory health insurance reimbursement under SHI G-DRG framework supports ophthalmic implant procedures, while AMNOG benefit assessment governs added-benefit reimbursement for novel hydrogel-API combinations. Merck KGaA's 2025 acquisition of SpringWorks Therapeutics, valued at approximately USD 3.4 Billion, broadened the company's rare disease and oncology pipeline including hydrogel-formulated candidates.

China generated USD 738 Million in 2025 hydrogel for drug delivery market revenue and is projected to grow at a 10.6% CAGR through 2034, the fastest among the four reported countries. The National Medical Products Administration regulatory framework, modernized through the priority-review and conditional approval pathways, supports faster commercialization of hydrogel-based drug delivery products. Domestic R&D at Chinese Academy of Sciences (Changchun Institute of Applied Chemistry), University of Science and Technology of China, and Sun Yat-sen University has driven peer-reviewed publications on stimuli-responsive injectable hydrogels for cancer chemo-immunotherapy. Domestic chemical producers including LG Chem (regional operations), Sumitomo Seika, and Sinopec support polymer supply chain integration.

Japan posted USD 397 Million in 2025 with a country CAGR of 8.6% projected through 2034. The Pharmaceuticals and Medical Devices Agency regulates hydrogel drug-device combinations under the Pharmaceutical and Medical Device Act, while National Health Insurance reimbursement supports adoption of approved hydrogel products. Domestic R&D at Tokyo University, Kyoto University, and Osaka University has supported published advances in self-healing hydrogels and 3D bioprinting hydrogel bioinks. Sanyo Chemical Industries, Sumitomo Seika, and Nippon Shokubai anchor domestic polymer supply, while pharmaceutical OEMs Takeda, Astellas, and Otsuka support hydrogel formulation R&D for ophthalmic and oncology applications.

Hydrogel for Drug Delivery Market Size Country

Get More Information about this report -

Request Free Sample Report

Key Market Segment

By Polymer Origin

Natural Hydrogels
Synthetic Hydrogels
Hybrid Hydrogels

By Delivery Route

Injectable
Oral
Topical & Transdermal
Ocular
Others

By Application

Cancer Therapy
Wound Healing
Ophthalmic Drug Delivery
Tissue Engineering & Regenerative Medicine
Others

By End User

Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Research & Academic Institutes
Ambulatory Surgical Centers (ASCs)

By Regional Coverage

North America
Latin America
East Asia And Pacific
Sea And South Asia
Eastern Europe
Western Europe
Middle East & Africa

Report Attribute	Details
Market size (2025)	USD 8.85 B
Forecast Revenue (2034)	USD 18.40 B
CAGR (2025-2034)	8.5%
Historical data	2021-2025
Base Year For Estimation	2025
Forecast Period	2026-2034
Report coverage	Revenue Forecast, Competitive Landscape, Market Dynamics, Growth Factors, Trends and Recent Developments
Segments covered	By Polymer Origin, (Natural Hydrogels, Synthetic Hydrogels, Hybrid Hydrogels), By Delivery Route, (Injectable, Oral, Topical & Transdermal, Ocular, Others), By Application, (Cancer Therapy, Wound Healing, Ophthalmic Drug Delivery, Tissue Engineering & Regenerative Medicine, Others), By End User, (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, Ambulatory Surgical Centers (ASCs)),
Research Methodology	Primary Research- 100 Interviews of Stakeholders Secondary Research Desk Research
Regional scope	North America (United States, Canada, Mexico) Latin America (Brazil, Argentina, Columbia) East Asia And Pacific (China, Japan, South Korea, Australia, Cambodia, Fiji, Indonesia) Sea And South Asia (India, Singapore, Thailand, Taiwan, Malaysia) Eastern Europe (Poland, Russia, Czech Republic, Romania) Western Europe (Germany, U.K., France, Spain, Itlay) Middle East & Africa (GCC Countries, Egypt, Nigeria, South Africa, Israel)
Competitive Landscape	GENENTECH INC. (ROCHE), UROGEN PHARMA LTD., PACIRA BIOSCIENCES INC., OCULAR THERAPEUTIX INC., JOHNSON & JOHNSON, CARDINAL HEALTH INC., INTEGRA LIFESCIENCES HOLDINGS CORPORATION, MERCK KGAA, ASHLAND GLOBAL HOLDINGS INC., THE LUBRIZOL CORPORATION, UPM BIOMEDICALS OY, PAUL HARTMANN AG, CONVATEC GROUP PLC, SMITH & NEPHEW PLC, 3M COMPANY, COLOPLAST A/S, B. BRAUN MELSUNGEN AG, ROYAL DSM N.V., BASF SE, NEXGEL INC., BIOMIQ INC., BEIERSDORF AG, ROQUETTE FRÈRES, AXELGAARD MANUFACTURING CO. LTD., GALDERMA SA, SANYO CHEMICAL INDUSTRIES LTD., LG CHEM LTD., SUMITOMO SEIKA CHEMICALS CO. LTD., NIPPON SHOKUBAI CO. LTD., THE COOPER COMPANIES INC., Others
Customization Scope	Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs. We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF).

Frequently Asked Questions

How big is the Hydrogel for Drug Delivery Market?

The Global Hydrogel for Drug Delivery Market was valued at USD 8.24 Billion in 2024 and is projected to reach USD 18.40 Billion by 2034, growing at a CAGR of 8.5% during the forecast period 2026–2034.

Who are the major players in the Hydrogel for Drug Delivery Market?

GENENTECH INC. (ROCHE), UROGEN PHARMA LTD., PACIRA BIOSCIENCES INC., OCULAR THERAPEUTIX INC., JOHNSON & JOHNSON, CARDINAL HEALTH INC., INTEGRA LIFESCIENCES HOLDINGS CORPORATION, MERCK KGAA, ASHLAND GLOBAL HOLDINGS INC., THE LUBRIZOL CORPORATION, UPM BIOMEDICALS OY, PAUL HARTMANN AG, CONVATEC GROUP PLC, SMITH & NEPHEW PLC, 3M COMPANY, COLOPLAST A/S, B. BRAUN MELSUNGEN AG, ROYAL DSM N.V., BASF SE, NEXGEL INC., BIOMIQ INC., BEIERSDORF AG, ROQUETTE FRÈRES, AXELGAARD MANUFACTURING CO. LTD., GALDERMA SA, SANYO CHEMICAL INDUSTRIES LTD., LG CHEM LTD., SUMITOMO SEIKA CHEMICALS CO. LTD., NIPPON SHOKUBAI CO. LTD., THE COOPER COMPANIES INC., Others

Which segments covered the Hydrogel for Drug Delivery Market?

By Polymer Origin, (Natural Hydrogels, Synthetic Hydrogels, Hybrid Hydrogels), By Delivery Route, (Injectable, Oral, Topical & Transdermal, Ocular, Others), By Application, (Cancer Therapy, Wound Healing, Ophthalmic Drug Delivery, Tissue Engineering & Regenerative Medicine, Others), By End User, (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, Ambulatory Surgical Centers (ASCs)),

How can this market research report help my business make strategic decisions?

Our market research reports provide actionable intelligence, including verified market size data, CAGR projections, competitive benchmarking, and segment-level opportunity analysis. These insights support strategic planning, investment decisions, product development, and market entry strategies for enterprises and startups alike.

How frequently is the data updated?

We continuously monitor industry developments and update our reports to reflect regulatory changes, technological advancements, and macroeconomic shifts. Updated editions ensure you receive the latest market intelligence.

Report ID IR1597

Published 21 Jul 2026

4/5

( 71638 )

Request Sample

Share This Report

Select Licence Type

Single User

US$ 3350

Multi User

US$ 4950

Corporate

US$ 6950

Excel Pack

US$ 1100

Buy Now

Connect with our sales team

sales@intelevoresearch.com

Global Hydrogel for Drug Delivery Market Size, Share | CAGR of 8.5%

Quick Navigation Show/Hide

Report Overview

Get More Information about this report -

Market Definition and Scope

Key Takeaways

Key Insights Summary

Competitive Landscape Overview

Competitive Landscape Matrix

By Polymer Origin

By Delivery Route

By Application

By End User

Regional Analysis

Country Analysis

Get More Information about this report -

Key Player Analysis

Driver

Rising Demand for Targeted and Controlled Drug Delivery Systems

Restraint

Complex Manufacturing Processes and Regulatory Challenges

Trend

Growing Adoption of Smart and Stimuli-Responsive Hydrogels

Opportunity

Expanding Applications in Regenerative Medicine and Biologics Delivery

Investment and M&A Activity

Recent Developments

Frequently Asked Questions

How big is the Hydrogel for Drug Delivery Market?

Who are the major players in the Hydrogel for Drug Delivery Market?

Which segments covered the Hydrogel for Drug Delivery Market?

How can this market research report help my business make strategic decisions?

How frequently is the data updated?

➮ Related Reports

US Liquid Biopsy Market

Liquid Biopsy Market

US Hydrogel for Drug Delivery Market

US Tumor-Infiltrating Lymphocyte Therapy Market

US Continuous Glucose Responsive Insulin Market

Decellularized Tissue Market

US Decellularized Tissue Market

Continuous Glucose Responsive Insulin Market

Tumor-Infiltrating Lymphocyte Therapy Market

Targeted Protein Degradation Market

Share This Report

Select Licence Type

Connect with our sales team

Why IntelEvoResearch